1. Home
  2. MDXH vs ZYXI Comparison

MDXH vs ZYXI Comparison

Compare MDXH & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • ZYXI
  • Stock Information
  • Founded
  • MDXH 2003
  • ZYXI 1996
  • Country
  • MDXH Belgium
  • ZYXI United States
  • Employees
  • MDXH N/A
  • ZYXI N/A
  • Industry
  • MDXH
  • ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • MDXH
  • ZYXI Health Care
  • Exchange
  • MDXH Nasdaq
  • ZYXI Nasdaq
  • Market Cap
  • MDXH 73.3M
  • ZYXI 66.5M
  • IPO Year
  • MDXH 2021
  • ZYXI N/A
  • Fundamental
  • Price
  • MDXH $1.76
  • ZYXI $2.41
  • Analyst Decision
  • MDXH Buy
  • ZYXI Buy
  • Analyst Count
  • MDXH 1
  • ZYXI 3
  • Target Price
  • MDXH $6.00
  • ZYXI $10.25
  • AVG Volume (30 Days)
  • MDXH 55.7K
  • ZYXI 217.8K
  • Earning Date
  • MDXH 05-05-2025
  • ZYXI 04-29-2025
  • Dividend Yield
  • MDXH N/A
  • ZYXI N/A
  • EPS Growth
  • MDXH N/A
  • ZYXI N/A
  • EPS
  • MDXH N/A
  • ZYXI 0.09
  • Revenue
  • MDXH $90,049,000.00
  • ZYXI $192,354,000.00
  • Revenue This Year
  • MDXH $23.38
  • ZYXI N/A
  • Revenue Next Year
  • MDXH $16.84
  • ZYXI $23.16
  • P/E Ratio
  • MDXH N/A
  • ZYXI $28.00
  • Revenue Growth
  • MDXH 28.29
  • ZYXI 4.36
  • 52 Week Low
  • MDXH $1.35
  • ZYXI $1.93
  • 52 Week High
  • MDXH $3.50
  • ZYXI $12.19
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 66.56
  • ZYXI 37.83
  • Support Level
  • MDXH $1.51
  • ZYXI $2.09
  • Resistance Level
  • MDXH $1.64
  • ZYXI $2.24
  • Average True Range (ATR)
  • MDXH 0.08
  • ZYXI 0.16
  • MACD
  • MDXH 0.04
  • ZYXI 0.19
  • Stochastic Oscillator
  • MDXH 93.02
  • ZYXI 75.00

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

About ZYXI Zynex Inc.

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Share on Social Networks: